Can Aveanna Drive a Strong Third Quarter on Care-Delivery Momentum?

Aveanna Healthcare (AVAH) projects a strong third quarter for 2025, with preliminary results indicating revenues of $616-$624 million, representing 21%-22.6% year-over-year growth, alongside net income of $11-$15 million (over 120% growth) and adjusted EBITDA of $77-$81 million (61%-69% growth). This robust performance is driven by improved reimbursement rates, expanded preferred-payer relationships, enhanced caregiver capacity, and operational efficiencies. The company's shares have gained 105.9% year-to-date, significantly outperforming peers and broader markets, with a durable long-term outlook supported by raised full-year guidance and favorable industry trends in home healthcare.

Analysis

Aveanna Healthcare (AVAH) is poised for a robust third quarter of 2025, with preliminary results indicating significant financial growth. The company projects revenues of $616-$624 million, reflecting a substantial 21.0%-22.6% year-over-year increase, alongside an estimated net income of $11-$15 million, marking 126%-135% growth. Adjusted EBITDA is also expected to rise by 61%-69% to $77-$81 million, underscoring strong operational momentum and profitability.

This strong performance is primarily driven by improved reimbursement rates, expanded preferred-payer relationships, and enhanced caregiver recruitment and retention, which have boosted care-hour delivery. Management's confidence is further evidenced by a raised full-year guidance to over $2.3 billion in revenues and $270 million in adjusted EBITDA, signaling durable structural growth tailwinds and improved long-term earnings visibility. The balanced segment mix, including Private Duty Services and Home Health & Hospice, contributes to reduced concentration risk.

AVAH shares have significantly outperformed the market, gaining 105.9% year-to-date, surpassing the Medical Outpatient and Home Healthcare Market's 5.1% and the S&P 500's 18% increase. Despite this strong appreciation, AVAH trades at approximately 0.8x forward 12-month price-to-sales, positioning it below some peers like Addus HomeCare (ADUS) at 1.5x, which may suggest a compelling valuation. The company currently holds a Zacks Rank #1 (Strong Buy).

Key Decisions for Investors

• Investors should closely monitor the official Q3 2025 earnings report on November 6 for confirmation of these strong preliminary figures and any further updates to full-year guidance.
• Given the robust growth projections, strong market outperformance, and positive long-term outlook, consider Aveanna Healthcare (AVAH) for potential growth exposure within the home healthcare sector.
• Evaluate AVAH's current valuation of 0.8x forward price-to-sales relative to its peers to assess potential entry points or adjustments to existing positions.
• Track the company's progress in securing improved reimbursement rates and expanding preferred-payer partnerships, as these are critical for sustained revenue quality and margin stability.